Literature DB >> 35035637

Extended antithrombotic therapy for secondary prevention of cardiovascular events: A tool for pharmacists.

Kari Rustad1, Kirsten Tangedal1, Samantha Tri1, William Semchuk1.   

Abstract

Entities:  

Year:  2021        PMID: 35035637      PMCID: PMC8756364          DOI: 10.1177/17151635211045973

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN: 1715-1635


× No keyword cloud information.
  14 in total

1.  Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.

Authors:  Laura Mauri; Dean J Kereiakes; Robert W Yeh; Priscilla Driscoll-Shempp; Donald E Cutlip; P Gabriel Steg; Sharon-Lise T Normand; Eugene Braunwald; Stephen D Wiviott; David J Cohen; David R Holmes; Mitchell W Krucoff; James Hermiller; Harold L Dauerman; Daniel I Simon; David E Kandzari; Kirk N Garratt; David P Lee; Thomas K Pow; Peter Ver Lee; Michael J Rinaldi; Joseph M Massaro
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Long-term Tolerability of Ticagrelor for the Secondary Prevention of Major Adverse Cardiovascular Events: A Secondary Analysis of the PEGASUS-TIMI 54 Trial.

Authors:  Marc P Bonaca; Deepak L Bhatt; Ton Oude Ophuis; P Gabriel Steg; Robert Storey; Marc Cohen; Julia Kuder; Kyungah Im; Giulia Magnani; Andrzej Budaj; Pierre Theroux; Christian Hamm; Jindrich Špinar; Robert G Kiss; Anthony J Dalby; Felix A Medina; Frederic Kontny; Philip E Aylward; Eva C Jensen; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2016-07-01       Impact factor: 14.676

3.  2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Glenn N Levine; Eric R Bates; John A Bittl; Ralph G Brindis; Stephan D Fihn; Lee A Fleisher; Christopher B Granger; Richard A Lange; Michael J Mack; Laura Mauri; Roxana Mehran; Debabrata Mukherjee; L Kristin Newby; Patrick T O'Gara; Marc S Sabatine; Peter K Smith; Sidney C Smith
Journal:  J Am Coll Cardiol       Date:  2016-03-29       Impact factor: 24.094

4.  Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease.

Authors:  John W Eikelboom; Stuart J Connolly; Jackie Bosch; Gilles R Dagenais; Robert G Hart; Olga Shestakovska; Rafael Diaz; Marco Alings; Eva M Lonn; Sonia S Anand; Petr Widimsky; Masatsugu Hori; Alvaro Avezum; Leopoldo S Piegas; Kelley R H Branch; Jeffrey Probstfield; Deepak L Bhatt; Jun Zhu; Yan Liang; Aldo P Maggioni; Patricio Lopez-Jaramillo; Martin O'Donnell; Ajay K Kakkar; Keith A A Fox; Alexander N Parkhomenko; Georg Ertl; Stefan Störk; Matyas Keltai; Lars Ryden; Nana Pogosova; Antonio L Dans; Fernando Lanas; Patrick J Commerford; Christian Torp-Pedersen; Tomek J Guzik; Peter B Verhamme; Dragos Vinereanu; Jae-Hyung Kim; Andrew M Tonkin; Basil S Lewis; Camilo Felix; Khalid Yusoff; P Gabriel Steg; Kaj P Metsarinne; Nancy Cook Bruns; Frank Misselwitz; Edmond Chen; Darryl Leong; Salim Yusuf
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

Review 5.  Assessment and management of acute coronary syndromes (ACS): a Canadian perspective on current guideline-recommended treatment--part 1: non-ST-segment elevation ACS.

Authors:  David H Fitchett; Pierre Theroux; James M Brophy; Warren J Cantor; Jafna L Cox; Milan Gupta; Heather Kertland; Shamir R Mehta; Robert C Welsh; Shaun G Goodman
Journal:  Can J Cardiol       Date:  2011 Nov-Dec       Impact factor: 5.223

6.  ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2016 Appropriate Use Criteria for Coronary Revascularization in Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and the Society of Thoracic Surgeons.

Authors:  Manesh R Patel; John H Calhoon; Gregory J Dehmer; James Aaron Grantham; Thomas M Maddox; David J Maron; Peter K Smith
Journal:  J Am Coll Cardiol       Date:  2016-12-21       Impact factor: 24.094

7.  Synergy of Dual Pathway Inhibition in Chronic Cardiovascular Disease.

Authors:  Michiel Coppens; Jeffrey I Weitz; John W A Eikelboom
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

Review 8.  2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy.

Authors:  Shamir R Mehta; Kevin R Bainey; Warren J Cantor; Marie Lordkipanidzé; Guillaume Marquis-Gravel; Simon D Robinson; Matthew Sibbald; Derek Y So; Graham C Wong; Joseph G Abunassar; Margaret L Ackman; Alan D Bell; Raymond Cartier; James D Douketis; Patrick R Lawler; Michael S McMurtry; Jacob A Udell; Sean van Diepen; Subodh Verma; G B John Mancini; John A Cairns; Jean-François Tanguay
Journal:  Can J Cardiol       Date:  2017-12-19       Impact factor: 5.223

Review 9.  Focused 2012 update of the Canadian Cardiovascular Society guidelines for the use of antiplatelet therapy.

Authors:  Jean-François Tanguay; Alan D Bell; Margaret L Ackman; Robert D C Bauer; Raymond Cartier; Wee-Shian Chan; James Douketis; André Roussin; Gregory Schnell; Subodh Verma; Graham Wong; Shamir R Mehta
Journal:  Can J Cardiol       Date:  2013-08-23       Impact factor: 5.223

10.  Ischaemic risk and efficacy of ticagrelor in relation to time from P2Y12 inhibitor withdrawal in patients with prior myocardial infarction: insights from PEGASUS-TIMI 54.

Authors:  Marc P Bonaca; Deepak L Bhatt; P Gabriel Steg; Robert F Storey; Marc Cohen; Kyungah Im; Ton Oude Ophuis; Andrej Budaj; Shinya Goto; José López-Sendón; Rafael Diaz; Anthony Dalby; Frans Van de Werf; Diego Ardissino; Gilles Montalescot; Philip Aylward; Giulia Magnani; Eva C Jensen; Peter Held; Eugene Braunwald; Marc S Sabatine
Journal:  Eur Heart J       Date:  2015-10-21       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.